Cancer stem cells in triple-negative breast cancer: A potential target and prognostic marker

Christopher J. O'Conor, Tiffany Chen, Iván González, Dengfeng Cao, Yan Peng

Research output: Contribution to journalReview article

3 Citations (Scopus)

Abstract

Triple-negative breast cancer (TNBC) is an aggressive disease with poor outcome, and lacks targeted therapy. Recent studies suggest that cancer stem cells play an important role in tumorigenesis and tumor biology of TNBC. Both CD44+/CD24- and ALDH1+ breast cancer stem cells are enriched in TNBC and may contribute to the propensity of TNBC for chemotherapy resistance and tumor metastasis. There is new evidence to support the evaluation of cancer stem cells in TNBC for diagnostic purposes. Targeting cancer stem cells may also be a promising, novel strategy for the treatment of TNBC. This review highlights the current understanding of breast cancer stem cells in TNBC, with focus on CD44+/CD24- and ALDH1+ breast cancer stem cells. It is our hope that this work provides insight into the potential role of cancer stem cells in the prognostication and therapeutic targeting of TNBC.

Original languageEnglish (US)
Pages (from-to)813-820
Number of pages8
JournalBiomarkers in Medicine
Volume12
Issue number7
DOIs
StatePublished - Jul 1 2018

Fingerprint

Triple Negative Breast Neoplasms
Neoplastic Stem Cells
Stem cells
Breast Neoplasms
Tumors
Chemotherapy
Neoplasms
Carcinogenesis
Therapeutics
Neoplasm Metastasis
Drug Therapy

Keywords

  • biomarkers
  • breast cancer
  • cancer stem cells
  • triple-negative breast cancer

ASJC Scopus subject areas

  • Drug Discovery
  • Clinical Biochemistry
  • Biochemistry, medical

Cite this

Cancer stem cells in triple-negative breast cancer : A potential target and prognostic marker. / O'Conor, Christopher J.; Chen, Tiffany; González, Iván; Cao, Dengfeng; Peng, Yan.

In: Biomarkers in Medicine, Vol. 12, No. 7, 01.07.2018, p. 813-820.

Research output: Contribution to journalReview article

O'Conor, Christopher J. ; Chen, Tiffany ; González, Iván ; Cao, Dengfeng ; Peng, Yan. / Cancer stem cells in triple-negative breast cancer : A potential target and prognostic marker. In: Biomarkers in Medicine. 2018 ; Vol. 12, No. 7. pp. 813-820.
@article{31875fa6dafd49aebf19958d6b240c3b,
title = "Cancer stem cells in triple-negative breast cancer: A potential target and prognostic marker",
abstract = "Triple-negative breast cancer (TNBC) is an aggressive disease with poor outcome, and lacks targeted therapy. Recent studies suggest that cancer stem cells play an important role in tumorigenesis and tumor biology of TNBC. Both CD44+/CD24- and ALDH1+ breast cancer stem cells are enriched in TNBC and may contribute to the propensity of TNBC for chemotherapy resistance and tumor metastasis. There is new evidence to support the evaluation of cancer stem cells in TNBC for diagnostic purposes. Targeting cancer stem cells may also be a promising, novel strategy for the treatment of TNBC. This review highlights the current understanding of breast cancer stem cells in TNBC, with focus on CD44+/CD24- and ALDH1+ breast cancer stem cells. It is our hope that this work provides insight into the potential role of cancer stem cells in the prognostication and therapeutic targeting of TNBC.",
keywords = "biomarkers, breast cancer, cancer stem cells, triple-negative breast cancer",
author = "O'Conor, {Christopher J.} and Tiffany Chen and Iv{\'a}n Gonz{\'a}lez and Dengfeng Cao and Yan Peng",
year = "2018",
month = "7",
day = "1",
doi = "10.2217/bmm-2017-0398",
language = "English (US)",
volume = "12",
pages = "813--820",
journal = "Biomarkers in Medicine",
issn = "1752-0363",
publisher = "Future Medicine Ltd.",
number = "7",

}

TY - JOUR

T1 - Cancer stem cells in triple-negative breast cancer

T2 - A potential target and prognostic marker

AU - O'Conor, Christopher J.

AU - Chen, Tiffany

AU - González, Iván

AU - Cao, Dengfeng

AU - Peng, Yan

PY - 2018/7/1

Y1 - 2018/7/1

N2 - Triple-negative breast cancer (TNBC) is an aggressive disease with poor outcome, and lacks targeted therapy. Recent studies suggest that cancer stem cells play an important role in tumorigenesis and tumor biology of TNBC. Both CD44+/CD24- and ALDH1+ breast cancer stem cells are enriched in TNBC and may contribute to the propensity of TNBC for chemotherapy resistance and tumor metastasis. There is new evidence to support the evaluation of cancer stem cells in TNBC for diagnostic purposes. Targeting cancer stem cells may also be a promising, novel strategy for the treatment of TNBC. This review highlights the current understanding of breast cancer stem cells in TNBC, with focus on CD44+/CD24- and ALDH1+ breast cancer stem cells. It is our hope that this work provides insight into the potential role of cancer stem cells in the prognostication and therapeutic targeting of TNBC.

AB - Triple-negative breast cancer (TNBC) is an aggressive disease with poor outcome, and lacks targeted therapy. Recent studies suggest that cancer stem cells play an important role in tumorigenesis and tumor biology of TNBC. Both CD44+/CD24- and ALDH1+ breast cancer stem cells are enriched in TNBC and may contribute to the propensity of TNBC for chemotherapy resistance and tumor metastasis. There is new evidence to support the evaluation of cancer stem cells in TNBC for diagnostic purposes. Targeting cancer stem cells may also be a promising, novel strategy for the treatment of TNBC. This review highlights the current understanding of breast cancer stem cells in TNBC, with focus on CD44+/CD24- and ALDH1+ breast cancer stem cells. It is our hope that this work provides insight into the potential role of cancer stem cells in the prognostication and therapeutic targeting of TNBC.

KW - biomarkers

KW - breast cancer

KW - cancer stem cells

KW - triple-negative breast cancer

UR - http://www.scopus.com/inward/record.url?scp=85049669969&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85049669969&partnerID=8YFLogxK

U2 - 10.2217/bmm-2017-0398

DO - 10.2217/bmm-2017-0398

M3 - Review article

C2 - 29902924

AN - SCOPUS:85049669969

VL - 12

SP - 813

EP - 820

JO - Biomarkers in Medicine

JF - Biomarkers in Medicine

SN - 1752-0363

IS - 7

ER -